The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

New tools, treatment options, and precision medicine developments are leading to better quality of life and survival for ...

and lifestyle changes Chronic obstructive pulmonary disease, commonly referred to as COPD, is a group of progressive lung diseases. An estimated 32 million people in the United States have COPD.

A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...

Explore the future of the COPD market with our comprehensive report covering 68 geographic markets. Forecast drug sales growth from $17.4B in 2023 to $42.2B by 2033, driven by the US market. Gain ...

TPU scientists as part of an international scientific collaboration analyzed the global need for medical care for patients ...

HealthDay News — Certain groups of physical multimorbidity may be associated with a higher risk of subsequent depression, according to a study published online May 13 in Communications Medicine.

Emergency crews pulled nine adults from a sinking sailboat in the choppy waters of the San Francisco bay. Dr. Daniel Ngui, BSc, (P.T.), MD, CFPC, FCFP, Family Physician, discusses What is Chronic ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil ...